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Macrophages play a major role in the immune system, both as antimicrobial effector cells
and as immunoregulatory cells, which induce, suppress or modulate adaptive immune
responses. These key aspects of macrophage biology are fundamentally driven by the
phenotype of macrophage arginine metabolism that is prevalent in an evolving or ongo-
ing immune response. M1 macrophages express the enzyme nitric oxide synthase, which
metabolizes arginine to nitric oxide (NO) and citrulline. NO can be metabolized to further
downstream reactive nitrogen species, while citrulline might be reused for efficient NO
synthesis via the citrulline–NO cycle. M2 macrophages are characterized by expression of
the enzyme arginase, which hydrolyzes arginine to ornithine and urea. The arginase path-
way limits arginine availability for NO synthesis and ornithine itself can further feed into the
important downstream pathways of polyamine and proline syntheses, which are important
for cellular proliferation and tissue repair. M1 versus M2 polarization leads to opposing out-
comes of inflammatory reactions, but depending on the context, M1 and M2 macrophages
can be both pro- and anti-inflammatory. Notably, M1/M2 macrophage polarization can be
driven by microbial infection or innate danger signals without any influence of adaptive
immune cells, secondarily driving the T helper (Th)1/Th2 polarization of the evolving adap-
tive immune response. Since both arginine metabolic pathways cross-inhibit each other on
the level of the respective arginine break-down products andTh1 andTh2 lymphocytes can
drive or amplify macrophage M1/M2 dichotomy via cytokine activation, this forms the basis
of a self-sustaining M1/M2 polarization of the whole immune response. Understanding the
arginine metabolism of M1/M2 macrophage phenotypes is therefore central to find new
possibilities to manipulate immune responses in infection, autoimmune diseases, chronic
inflammatory conditions, and cancer.
Keywords: macrophage, M1 and M2, arginine, arginase, nitric oxide synthase, immunoregulation, amino acid
transporter
INTRODUCTION: ARGININE IN THE CENTER OF M1/M2
MACROPHAGE DICHOTOMY
Macrophages are highly versatile cells, which are (i) crucial
for infection control (“kill/fight mode”) and tissue homeostasis
(“default mode”, phagocytosing cellular debris) and (ii) involved
in disease pathophysiology in cancer, autoimmunity, metabolic,
and fibrotic disorders (1). Macrophages react to a wide variety
of external stimuli and are able to produce a multitude of effec-
tor molecules for intercellular communication, microbial defense,
and modulation of inflammatory reactions (1). They induce, sup-
press, or modulate both innate and adaptive immune responses.
Considering this enormous complexity it is reasonable to deduce
classification schemes to create order and sense in the experimental
results of macrophage research (2, 3). Potential macrophage diver-
sity, both in terms of activation states, surface marker expression,
metabolic phenotype, and interspecies differences clearly requires
rigid standards for experimental set-up and reporting (4). While
undue simplification hampers the comparability between studies
(4), a reductionist approach tries to avoid getting lost in the com-
plexities of macrophage biology and has both enormous power
for the explanation of reality and can be the basis for experi-
mentally testing of hypotheses. One should never forget that even
the most sophisticated modern computers are based on the “0–1”
dichotomy!
One of the most fruitful and reasonable classification of
macrophages relates to their two main functions, namely, to
kill/fight or to heal/fix. Within this classification view, macrophage
biology is driven by two phenotypes (M1 for killing/fighting
versus M2 for healing/fixing), which are also relevant in an
evolving or ongoing immune response (5). M1 or M2 domi-
nant macrophages then direct T lymphocytes to produce Th1 or
Th2 responses, respectively, to further amplify M1 or M2 type
responses in positive feed-back loops stabilizing the predominant
immune phenotype in the respective setting of infection, tumor,
or inflammation. The M1/M2 macrophage classification can be
condensed into two opposing pathways for the metabolism of one
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amino acid: the preference of macrophages to metabolize argi-
nine via nitric oxide synthase (NOS) to NO and citrulline or via
arginase to ornithine and urea defines them as M1 (NOS) or M2
(arginase) macrophages (5). NOS or arginase are enzymes that
catalyze a “reaction,” but we will use “pathway” here to illumi-
nate that they are part of multi-enzyme pathways producing other
physiologically important products.
In this introductory review, we will describe macrophage
arginine metabolism, its functional consequences and how the
macrophage arginine metabolic phenotype defines the two oppos-
ing M1 and M2 types of macrophages. While various mole-
cules and features of macrophages are reciprocally or mutually
exclusively associated with the M1 versus M2 phenotype, the
dichotomous regulation of arginine metabolism is at the center
of the different functions that are associated with M1 and M2
macrophages.
ARGININE: ONE SMALL AMINO ACID FOR MACROPHAGE
METABOLISM, A GIANT CONTROLLER FOR MAMMALIAN
(PATHO-)PHYSIOLOGY
Mammalian arginine metabolism is complex both at the level
of the whole organism (6, 7) and at the level of the individual
cell types (8) and we would like to adopt the term “argenomics”
that was suggested by Sidney M. Morris Jr (7) for the regulation
of gene expression via arginine availability in an even broader
sense for the whole fascinating complexity of arginine-driven cel-
lular regulation. Before focusing in on arginine metabolism of
macrophages and its determining role for the M1/M2 dichotomy,
let us first have a short overview on some historical facts relating
to arginine in mammalian physiology. The story started nearly
130 years ago, arginine was first isolated in 1886 and was iden-
tified as a component of animal proteins in 1895 (8). The role
of arginine in metabolic physiology was first demonstrated in
1932, when Krebs and Henseleit discovered the urea cycle. In 1981,
Windmueller and Spaeth reported that the small intestine is the
major source of citrulline for synthesis of arginine by the kidneys,
now called the intestinal–renal axis for arginine synthesis on an
organismal level (9). In 1987, it was shown that arginine is the
precursor for macrophage citrulline and nitrite synthesis (10) and
that arginine-derived NO is the elusive endothelium-derived relax-
ing factor (EDRF) (11, 12). Soon afterwards, NO was categorized
as physiologically active intermediate of the arginine to nitrite
(+nitrate) pathway in macrophages (13, 14) and endothelial cells
(15). The discovery of the fundamental role of arginine-derived
NO for human cardiovascular physiology already led to the award
of the Nobel Prize in 1998 to Robert F. Furchgott, Louis J. Ignarro,
and Ferid Murad. The importance of arginine has still risen since
then, it is now clear that immune cell arginine metabolism is fun-
damentally involved in cancer, inflammation, infections, fibrotic
diseases, pregnancy, and immune regulation in general (16–21). A
huge responsibility for a small molecule!
MACROPHAGE ARGININE AVAILABILITY: SEVERAL ROADS
LEAD TO ONE AMINO ACID
On the level of the whole organism, arginine is a non-essential
amino acid for healthy adult humans,but it has to be supplemented
during growth or various disease states (6, 7) and has thus been
characterized as a semi- or conditionally essential amino acid.
Average arginine ingestion with a Western style diet is around
4–5 g/day and the normal plasma arginine level is 100–200µM.
Besides dietary intake, arginine is derived from cellular protein
break-down or endogenous de novo arginine production. Mam-
malian arginine biosynthesis (Figure 1) involves mainly the amino
acids glutamine, ornithine, and citrulline and the involved enzy-
matic steps are compartmentalized in different tissues and also on
the subcellular level so that not all reactions can take place in each
individual cell type or tissue. For a more detailed description of the
chemical pathways of arginine metabolism, the reader is referred
to the excellent review by Wu and Morris (8). (i) Glutamine can
be converted to ornithine via glutaminase (yielding glutamate),
pyrroline-5-carboxylate synthetase (P5CS), which is almost exclu-
sively expressed in the intestinal mucosa, and ornithine amino-
transferase (OAT). (ii) Ornithine transcarbamylase (OTC) and
carbamoyl phosphate synthetase (CPS) are involved in the for-
mation of citrulline from ornithine. The enzymes are restricted
to the mitochondrial matrix of hepatocytes and epithelial cells
of small and (to a minor extent) large intestine. This reaction
is therefore a part of the hepatic urea cycle and also involved in
intestinal synthesis of citrulline, which is released into the circu-
lation. The proximal tubules of the kidneys take up most of the
circulating citrulline, which is then converted within the kidney
to arginine and again released into the circulation. (iii) Argini-
nosuccinate synthetase (ASS) and argininosuccinate lyase (ASL)
are cytosolic enzymes responsible for the biosynthesis of arginine
from citrulline (and aspartate as a co-substrate). While ASS and
ASL are expressed constitutively or inducibly in many different
cell types, their degree of expression, and the efficiency of their
catalytic pathways vary between different tissue types. On a whole
body level, the latter enzymatic steps form the basis of the so-called
intestinal–renal axis with intestinal production of citrulline (see
above) and renal synthesis of arginine (7).
M1 macrophages can also synthesize arginine in a cyclic fashion
(Figure 2): during NO synthesis, arginine is converted to NO and
citrulline via Nω-OH-arginine (22, 23). Murine macrophages have
long been known to (i) upregulate ASS and constitutively express
ASL when stimulated with the NOS-inducing agents lipopolysac-
charide (LPS) and IFN-γ (24) and (ii) to partially rescue NO
synthesis via citrulline uptake and ASS-mediated recycling to argi-
nine (25). This set of reactions via ASS and ASL forms the so-called
citrulline–NO cycle (26). The importance of this pathway for
the resynthesis of arginine to ensure sufficient substrate supply
for prolonged NO synthesis under arginine limitation has been
recently demonstrated in vivo in murine mycobacteria infection
(27). Despite the upregulation of ASS1, availability of arginine
remains a rate-limiting step for synthesis of NO and cellular uptake
of arginine also determines the amount of NO synthesized in case
of NOS and ornithine in case of arginase (28, 29).
CELLULAR UPTAKE OF ARGININE
The transmembranous arginine transport is one essential com-
ponent of cellular arginine metabolism and important for the
cells to perform their tasks. Amino acids do not pass mem-
branous lipid bilayers freely, but are transported via specialized
proteins. These amino acid transporters show different transport
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FIGURE 1 | Important pathways of mammalian arginine metabolism.
M1 and M2 macrophages are characterized by the metabolism of arginine via
NOS or arginase with important functional consequences. This dichotomy is
put into the context of other important pathways that can lead to the
synthesis or degradation of arginine in mammalian cells. For sake of clarity,
the diagram focuses on relevant enzymes (gray-shaded boxes), metabolites
(red boxes), and the position of NOS and arginase within the network is
highlighted. Various intermediate steps, by-products, or substrates are
omitted and the reader is referred to more extensive chemical reviews (see
text). ADC, arginine decarboxylase; AGAT, arginine:glycine amidinotransferase;
ASL, argininosuccinate lyase, ASS, argininosuccinate synthase; CP, carbamoyl
phosphate; CPS, CP synthase; NOS, nitric oxide synthase; OAT, ornithine
aminotransferase; ODC, ornithine decarboxylase; OTC, ornithine
transcarbamylase; P5C, pyrroline-5-carboxylate; P5CDH, P5C dehydrogenase;
P5CR, P5C reductase; P5CS, P5C synthase; PRODH, proline dehydrogenase;
SRS, spermidine synthase; SMS, spermine synthase.
FIGURE 2 | Arginine metabolism via NOS or arginase is at the center of
the M1/M2 polarization of macrophages. M1 and M2 macrophages are
characterized by the metabolism of arginine via NOS or arginase with
important functional consequences. Abbreviations: see Figure 1.
characteristics and specificities for the various amino acids, based
on their physicochemical properties. Arginine, like the other
cationic amino acids ornithine and lysine is preferentially taken
up via members of the solute carrier family 7 (SLC7) (30–32).
The subfamily of cationic amino acid transporters (CAT1–3, i.e.,
SLC7A1–3) recognizes exclusively cationic amino acids, while
members of the subfamily of heteromeric amino acid transporters,
y+LAT1 (SLC7A7) and y+LAT2 (SLC7A6), and b0,+AT transport
also neutral amino acids. CAT and y+LAT proteins are widely dis-
tributed in various tissue types. CAT proteins are the main trans-
porters for arginine uptake into cells, where the amino acid is then
used for protein synthesis and all arginine-dependent metabolic
pathways (7). CAT-1 is constitutively expressed in most tissues,
with the exception of the liver, while CAT-2B is cytokine-inducible.
CAT-2A is predominantly expressed in liver while CAT-3 is widely
expressed during embryonal development but largely restricted
to central nervous system and thymus in adults (30). In contrast
to CAT, y+LAT proteins exchange primarily extracellular neutral
against intracellular cationic amino acids and are therefore respon-
sible for arginine export rather then import (30, 32). b0,+AT is
expressed in epithelial cells of small intestine and kidney where it
is responsible for the (re)absorption of cationic amino acids and
cysteine (32). ATB0,+, a member of the SLC6 family, also trans-
ports both cationic and neutral amino acids and is expressed in
the apical membrane of epithelial cells in various tissues (30).
The complex regulation of CAT expression has been stud-
ied quite extensively (30, 32, 33), whereas comparatively little is
known about arginine transporter expression in most cells of the
hematopoetic system in general or the immune system specifi-
cally. Induction of CAT-2 has been shown in murine macrophages
upon both Th1 and Th2 cytokine stimulation (28), in murine
dendritic cells (DCs) by retinoic acid (RA) (34) and in murine
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microglia upon stimulation with IFN-γ+/− LPS (35). In contrast,
CAT-1 is either expressed constitutively (28) or even downreg-
ulated upon activation (35). Coordinated induction of CAT-2
and arginase (partially dependent on CAT-2 expression) has been
demonstrated in macrophages during murine allergic lung inflam-
mation, forming the basis of bleomycin-induced fibrosis (36) and
also in RA-activated DCs (34). On the other hand, sustained pro-
duction of NO in murine macrophages is also based on CAT-2
expression and CAT-2-mediated arginine uptake (37). The induc-
tion of CAT-2 in both M1 and M2 type murine macrophages
has been shown to differ quantitatively between different mouse
strains with important pathophysiological consequences: a dele-
tion in the SLC7A2 promoter of C57BL/6 mice leads to impaired
CAT-2 expression, reduced arginine uptake, and decreased suscep-
tibility to Leishmania infection as compared to BALB/c mice (38).
In contrast to murine macrophages, arginine transport is based on
system y+L in IFN-γ-activated human primary monocytes (39)
or LPS-stimulated alveolar macrophages (40), another example of
interspecies differences, which are so prominent in various aspects
of arginine metabolism in the immune system (17, 41, 42).
A crucial principle of immune cell signaling is the constitu-
tive preexistence or the activation-induced assembly of multi-
protein complexes that facilitate efficient transduction of stimuli.
In murine myeloid cells, enhanced arginine import via CAT-2 is
coupled to the induction of the arginine-catabolizing enzymes
arginase I (28) and NOS (28, 34, 35, 43). It remains to be analyzed if
(i) further similar higher-order structures or coordinated enzyme
induction, combining arginine transporters with specific arginine-
metabolizing proteins, can be found in macrophages and if (ii)
differences in M1 and M2 type cells do exist. This is a valid hypoth-
esis since amino acid transporters are not only final elements
of distinct signal transduction pathways, which immune cells
need for nutrient supply, but are also rather intricately involved
in complex metabolic networks in which they influence further
downstream signaling nodes and metabolic pathways (44). Inter-
estingly, the ornithine-derived polyamine spermine enhances the
expression of CAT-1 mRNA in human retinal pigment epithelial
cells (45). This observation leads to an interesting question regard-
ing macrophages: do M2 type macrophages increase their arginine
transport capacity via endogenous arginase-mediated synthesis
of polyamines, which would then further amplify arginase-based
metabolism in a positive feed-back loop? An alternative scenario
might result from the extracellular synthesis of ornithine after
arginase has been secreted (46) or liberated unspecifically dur-
ing cell death of myeloid cells (47). As ornithine is a cationic
amino acid and substrate of cationic amino acid transporters,
it (i) competitively inhibits arginine uptake and (ii) can be
exchanged for intracellular arginine via CAT transporter proteins
(31), potentially leading to a cellular depletion of arginine.
ARGININE CATABOLISM: A BIPOLAR WORLD IN
MACROPHAGES
In mammalian cells, arginine can be catabolized by four classes
of enzymes (Figure 1): NOS, arginase, arginine decarboxylase
(ADC), and arginine:glycine amidinotransferase (AGAT) (8).
Although the enzymes are of course regulated and expressed
in a cell-type-specific manner, the metabolism of arginine is
potentially complex since its downstream metabolites encompass
NO, urea, ornithine, citrulline, creatine, agmatine, glutamate, pro-
line, and the family of polyamines (7, 8). In macrophages, arginine
is a precursor for mainly two important metabolic pathways: it is
metabolized either by inducible nitric oxide synthase (iNOS) to
NO and citrulline or it is hydrolyzed by arginase to ornithine
and urea (Figure 2). This fundamental dichotomy of macrophage
arginine metabolism has wide ranging implications for their func-
tion as well as for the type and outcome of immune responses in
which these innate immune cells are involved in. Before these con-
sequences are discussed (see below), let us first look at the two
important distinct arginine enzymatic pathways in macrophages
in more detail.
NITRIC OXIDE SYNTHASE: ARGININE – NITRIC OXIDE PATHWAY
In 1980, Furchgott and co-workers discovered (i) the necessity of
an intact endothelium for relaxation of isolated blood vessels and
(ii) the presence of an endothelial cell-secreted unknown solu-
ble relaxing factor (EDRF) (48). In 1987, this factor was found
to be identical with NO (11) and arginine was revealed as the
precursor for NO synthesis in cardiovascular physiology (15). In
parallel studies, NO−2 and NO
−
3 were measured as end products of
a novel oxidation pathway expressed in macrophages upon stimu-
lation with LPS (49) or IFN-γ (50). Arginine was recognized as the
biological precursor molecule of nitrite/nitrate released from acti-
vated macrophages (10). Further studies demonstrated that NO
is an intermediate of macrophage arginine oxidation to the final
end products nitrite/nitrate (14) and that NO synthesis is required
for macrophage cytotoxic activity (22). In 1991, the enzyme con-
verting arginine to NO was purified, cloned, and was named NOS
(now known as neuronal NOS, nNOS) (51). Shortly after this, two
additional NOS isozymes were cloned: iNOS from macrophages
(52, 53) and endothelial NOS (eNOS) (54).
The three NOS isozymes differ in structure, distribution, regu-
lation, and synthetic capacity, but they catalyze the same reaction:
the incorporation of molecular oxygen and the release of NO
from the terminal guanidino nitrogen group of arginine and gen-
eration of citrulline as a byproduct (22). All NOS enzymes are
large homodimeric proteins with two functional domains: (i)
an N-terminal oxygenase and catalytic domain, which binds an
iron–protoporphyrin IX (heme) prosthetic group and the cofactor
tetrahydrobiopterin (BH4) and (ii) a C-terminal reductase domain
with binding sites for flavin mononucleotide (FMN) and flavin–
adenine dinucleotide (FAD). The catalytic reaction involves two
monooxygenation steps: (i) arginine is hydroxylated by O2 and
NADPH to form Nω-hydroxy-l-arginine, which is then (ii) oxi-
dized to yield NO and citrulline. All three NOS isoforms can also
synthesize superoxide in the absence of arginine and BH4. This
NOS-derived superoxide can react with NO to form peroxynitrite.
Both nNOS and eNOS are constitutively expressed enzymes and
calcium-dependent in their activity. In contrast, iNOS is regulated
via inducible transcription and synthesizes NO independent of
calcium since the essential subunit calmodulin is bound to iNOS
even at low intracellular calcium concentrations. Most promi-
nently known as microbicidal and inflammatory effector pathway
in macrophages (22), iNOS activity has also been demonstrated in
a variety of other cell types, e.g., hepatocytes (55), pulmonary
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epithelium (56), and colon epithelium (57). A variety of pro-
inflammatory cytokines (e.g., IL-1β, IFN-γ, or TNF-α), microbial
products (e.g., LPS), and hypoxia can induce macrophage iNOS
transcription, whereas other cytokines (e.g., IL-4, IL-10, TGF-β)
suppress iNOS gene transcription (58). Additive or synergistic
activities of combinations of multiple cytokines are most efficient
in inducing or suppressing iNOS gene expression. NO synthesis
can also be limited by arginine availability and/or on the level of
iNOS protein expression (59). NOS can further be inhibited by
endogenously produced asymmetric dimethylarginine (ADMA)
or pharmacologically by synthetic arginine analogs with substi-
tutions at the terminal guanidino group, e.g., Nω-monomethyl-
l-arginine (L-NMMA), Nω-nitro-l-arginine (L-NNA), or Nω-
nitro-l-arginine methyl ester (L-NAME). Once iNOS has been
translated, a prolonged production of potentially large amounts
of NO is detectable. NO can act via stimulation of soluble guany-
late cyclase to generate cyclic GMP within the target cell. Besides
its physiological role as guanylate cyclase stimulator, NO is also
a radical with a very short half-life of approximately 3–5 s and
it reacts with a variety of molecules leading to (i) further reac-
tive nitrogen species (RNS) like N2O3, peroxynitrite (ONOO−),
or nitronium ion
(
NO+2
)
in the presence of oxygen radicals (60)
and (ii) nitrosylated proteins with potentially altered or impaired
function.
ARGINASE: ARGININE – ORNITHINE PATHWAY
The enzyme arginase drives the second or alternative pathway of
arginine metabolism in macrophages, catalyzing the hydrolysis of
arginine to ornithine and urea. While arginase was known as an
enzyme of the hepatic urea cycle since the discovery of the latter
in 1932 by Krebs and Henseleit, it is also expressed in many non-
hepatic cells. There are two isozymes of arginase (arginase I and
arginase II), which catalyze the same biochemical reaction but dif-
fer in cellular expression, cell-type-specific regulation, and subcel-
lular localization (17, 61). Hepatic urea cycle arginase I is expressed
as a cytosolic enzyme, while human granulocyte arginase I is
found in the granular compartment (41) and arginase II is a mito-
chondrial enzyme (61). It was initially demonstrated that murine
macrophage arginase is inducible by PGE2 (62),Th2 cytokines,and
cAMP, both alone (62) and synergistically acting together (63). The
molecular details of this gene regulation were then clarified: the
transcription factors STAT-6 and CEBP/β assemble at an enhancer
element 3 kb upstream from the basal promoter of arginase I and
Th2 cytokine-mediated murine arginase I mRNA induction is con-
trolled by this mechanism (64). Meanwhile, human macrophage
arginase I expression was demonstrated by synergistic induction
with cAMP increasing treatments (PDE4 inhibition) in combi-
nation with IL-4 or TGF-β (65). The molecular details of this
induction were also clarified recently in the murine RAW264.7
macrophage cell line, involving STAT-6 and CEBP/β binding to an
IL-4 response element in the arginase I promoter (66). Another
layer of complexity comes into play by the demonstration of
pathogen-induced toll-like receptor (TLR)-mediated induction of
arginase I in murine macrophages (67, 68).
Ornithine serves as a substrate for ornithine decarboxylase
(ODC), a rate-limiting enzyme in the synthesis of polyamines.
Polyamines are small, polycationic molecules, which regulate a
multitude of cellular processes like DNA replication, protein trans-
lation, cell growth, and differentiation (69, 70). Much less is
known about an involvement of polyamines in immune reactions:
the polyamine spermine, e.g., inhibits pro-inflammatory cytokine
synthesis of human, LPS-stimulated PBMC (71), arginine trans-
port (72), and NO synthesis in rat (72) and murine macrophages
(73). Ornithine, via the enzyme OAT, is also a precursor amino acid
for the synthesis of proline, which itself is essential for the synthe-
sis of collagen. Accordingly, arginase-derived ornithine might be
important in tissue (re-)modeling processes. This hypothesis was
supported by studies that demonstrated an increase in arginase
levels in fibrotic lung disease (74) or allergic asthma (75, 76).
What are the biological functions of arginase-expressing
macrophages? While there is ample evidence, at least in the murine
system, of the fundamental role of NO-producing macrophages
for infection control (22), a multitude of pathophysiological sce-
narios have also been described in which arginase-expressing
macrophages are key players (17). In the initial groundbreak-
ing analysis on macrophage phenotypes during wound healing,
Mills and co-workers (77, 78) showed that arginase-expressing
and ornithine-producing macrophages were crucial for wound
healing as opposed to NO-producing macrophages, which dom-
inated the initial phase of antibacterial inflammation. The same
two macrophage phenotypes were then also correlated with tumor
growth (arginase/ornithine) or tumor killing (NOS/NO) (79).
Based on these dramatic differences in function, the two different
macrophage populations were then named as M1 and M2, based
on their route of arginine metabolism (Figure 2) (5). In general,
M2 type macrophages act as anti-inflammatory cells (“healing”
mode) via diversion of arginine away from NOS or via the synthesis
of downstream products derived from the ornithine that is gener-
ated via arginase (see above). For illustration, we want to list just a
few, more recently published examples for the role of macrophage
or, in this context, also DC arginase in (i) infection-induced
inflammation, (ii) immune evasion in tumor and infection, (iii)
regulation of fibrosis, and (iv) direct control of parasite growth. (i)
The anti-inflammatory property of macrophage arginase during
infection was shown in murine schistosomiasis where excessive tis-
sue injury is prevented by arginase-expressing macrophages due
to suppression of pro-inflammatory cytokines IL-12 and IL-23
and the maintenance of the Treg/Th17 balance (80). (ii) IL-6-
induced arginase 1 in DCs leads to downmodulation of MHC-II
and this is subsequently responsible for suppression of CD4+ T
cell-mediated antitumoral immunity (81). Immune evasion of
chronic Helicobacter pylori infection is mediated by arginase II
induction in gastric macrophages, due to inhibition of NOS-
mediated bacterial killing and suppression of pro-inflammatory
cytokine production (82). (iii) Macrophage arginase I restricts
Th2 cytokine driven inflammation and fibrosis in murine schis-
tosomiasis (83) although macrophage arginase itself can be pro-
fibrogenic via direct production of proline as collagen precursor
in schistosomiasis (84). (iv) Macrophage arginase-mediated syn-
thesis of polyamines enhances growth of intracellular Leishmania
parasites in murine macrophages (85) and arginase-expressing
granulocytes and the levels of arginase activities are markers
of disease severity in human visceral leishmaniasis and in HIV
infections (86–88).
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One further important consequence of macrophage arginase
expression is reduction of extracellular arginine. This is most
likely more apparent in the immediate microenvironment of M2
macrophages due to the continuous flux of nutrients and the argi-
nine synthetic capacity of the whole organism. Suppression of
T cell activation via arginine depletion has been studied quite
extensively in vitro (47, 89–91) and is known as one of the
prime immunosuppressive mechanisms of arginase-expressing
myeloid-derived suppressor cells (MDSC) (18). In contrast, its
role in macrophage-driven pathophysiology in vivo is still not
really clear in most relevant disease entities and needs to be ana-
lyzed in the future. We speculate that M2/arginase macrophages
might be more efficient in the induction of extracellular arginine
depletion since there is no intracellular reconstitutive mechanism
for arginine recycling for M2 macrophages as opposed to M1
macrophages, which can use the citrulline–NO rescue pathway.
Suppression of T cell activation, proliferation, and/or differen-
tiation by macrophage arginase I was shown in vivo in murine
disease models dominated by M2 macrophages, like schistoso-
miasis (80, 83) or leishmaniasis (92). Interestingly, extracellular
arginine depletion has also been shown to inhibit ERK1/2 activa-
tion and subsequently pro-inflammatory cytokine production in
LPS-stimulated macrophages (93). It will be interesting to study a
potential influence of intracellular arginine depletion on potential
pro-inflammatory signaling pathways within macrophages and to
analyze if there is regulation of innate immune responses and
macrophage polarization already at such basic level. Clearly, argi-
nine depletion does not inhibit immune responses broadly and
indiscriminately: important activation aspects of T cells (91, 94)
and granulocytes (95) are preserved in an arginine-depleted milieu
and other cellular responses, e.g., induction of arginine transport
protein CAT-1 (33), are even enhanced in eukaryotic cells under
arginine nutrient deprivation.
INTERACTIONS BETWEEN NOS AND ARGINASE PATHWAYS
Nitric oxide synthase and arginase can both antagonize or syn-
ergize in the generation of oxidative and nitrosative stress: inad-
equate supply of arginine (or the cofactor tetrahydrobiopterin)
leads to the production of superoxide
(
O−2
)
instead of NO, increas-
ing oxidative stress and also the production of peroxynitrite (22).
In general, though, mutually exclusive expression of iNOS and
arginase I in individual macrophages prevails (96) and there are
multiple cross-inhibitory interactions between the two arginine
metabolic pathways in macrophages: NOHA, the intermediate
product in NO synthesis, is a potent inhibitor of both arginase
isoforms (97). In non-macrophage cell types, it was also demon-
strated that NO is an effective inhibitor of ODC via nitrosylation
of the enzyme with consecutively reduced polyamine synthesis
(98). Arginase can limit arginine availability for NO synthesis, as
demonstrated by pharmacological arginase inhibition in different
types of macrophages (99). The expression of iNOS is translation-
ally controlled by the availability of arginine (100) and in murine
M2 macrophages, induced by the cytokine IL-13, iNOS translation,
and NO production are restricted by arginase-mediated arginine
depletion (59). Polyamines and/or polyamine aldehyde metabo-
lites can inhibit NO synthesis in murine and rat macrophages
(101). Spermine suppresses the induction of both iNOS and
CAT-2B arginine transporter (72) and inhibition of ODC-
mediated polyamine synthesis in murine macrophages enhances
LPS-induced iNOS expression and NO synthesis (102). Spermine
also inhibits H. pylori-induced iNOS protein translation in the
RAW264.7 macrophage cell line and siRNA-mediated ODC inhi-
bition enhances macrophage NO-mediated bacterial killing (103).
In summary, these biochemical crossregulatory interactions are
in line with the concept of two types of polarized macrophages –
M1/NOS versus M2/arginase – which are defined not only by the
intracellular fate of arginine, but – most importantly – also by its
associated functional consequences.
M1/NOS VERSUS M2/ARGINASE MACROPHAGES: NOVEL
ASPECTS
The earlier simplified scheme of “proinflammation=M1/Th1”
versus “anti-inflammation=M2/Th2” has meanwhile been clar-
ified as one possible scenario of a more broader conceptual
framework: M1 versus M2 polarization clearly leads to oppos-
ing outcomes of inflammatory reactions, but depending on the
inflammatory or infectious context, M1 and M2 macrophages can
be central players of both pro- or anti-inflammatory reactions.
Notably, M1/M2 macrophage polarization can be driven by micro-
bial infection or innate danger signals without any influence of
adaptive immune cells, secondarily driving the Th1/Th2 polariza-
tion of the evolving adaptive immune response (104). Microbial
stimulation of macrophages via TLRs leads to the activation of
certain transcription factors (e.g., NF-κB, AP-1), which upregu-
late pro-inflammatory cytokines like IFN-γ and TNF-α leading to
M1 macrophage polarization with high iNOS expression whereas
cytokines like IL-4 or IL-13 lead to STAT6 phosphorylation with
consecutive arginase expression and varying further aspects of M2
polarization (mannose receptor, Ym1, Fizz1).
Various novel aspects regarding the evolution of the M1/M2
macrophage polarization in light of the differential expression
of NOS versus arginase have been clarified recently and some
examples are summarized in the following sections:
NOVEL EXOGENOUS ENVIRONMENTAL FACTORS INFLUENCING THE
NOS/ARGINASE BALANCE
Tumor cells are known to metabolize glucose preferentially via
aerobic glycolysis, known as “Warburg phenomenon,” and this
leads to high concentrations of lactate in the tumor microenvi-
ronment. This tumor cell-derived lactic acid is a potent inducer
of arginase I expression in tumor-associated macrophages (TAM)
and these M2/arginase macrophages then foster tumor growth
(105). Since activated T cells also use aerobic glycolysis with con-
secutive production of lactic acid, it will be interesting to study
if the same mechanism of arginase I induction is also operative
in macrophage-T cell interactions. Gliadin, a major component
of cereal gluten, and therefore omnipresent in our daily food,
was shown to induce arginase I in human monocytes (106). A
parallel stimulation with IFN-γ leads to a reduction of cellular
arginine efflux via downregulation of the arginine export protein
y+LAT-2 (SLC7A6), thereby increasing intracellular availability of
arginine for gliadin-induced arginase (106). Finally, growth fac-
tors have also entered the M1/M2 macrophage world: in a hamster
model of visceral leishmaniasis, macrophage arginase I expression
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is driven by fibroblast growth factor-2 (FGF-2) and insulin-like
growth factor-1 (IGF-1), which both signal via STAT6 and are
amplified by co-stimulation with IL-4 (107).
INTRACELLULAR SIGNALING MODULES INVOLVED IN
M1(NOS)/M2(ARGINASE) POLARIZATION
The tyrosine phosphatase Shp2 restricts M2 macrophage polariza-
tion as demonstrated by the preferential polarization of Shp2−/−
macrophages into an M2 direction with enhanced arginase expres-
sion, associated with a better protection against schistosomiasis
(108). Also, PI3K/PTEN activity is involved in regulating arginase
expression in murine macrophages since deletion of PTEN leads
to M2 polarization via C/EBPβ and STAT3 (109). These results are
in line with earlier reports demonstrating that SHIP phosphatase
(which – like PTEN – also downregulates the PI3K pathway)
dampens M2 polarization and arginase I expression in different
types of tissue macrophages (110). Deacetylation of C/EBPβ is
required for its binding to a DNA enhancer element and its role
in IL-4-mediated arginase I induction in bone marrow-derived
murine macrophages (111).
AUTO- OR PARACRINE M1/M2 POLARIZATION
In murine macrophages, induction of arginase I by mycobacteria
is driven by an autocrine–paracrine signaling loop: TLR-MyD88
mediate induction of the cytokines IL-6, G-CSF, and IL-10, which
then induce arginase I, involving the transcription factors STAT3
and C/EBPβ (112). Respiratory syncytial virus (RSV) infection
induces production of IL-4 and IL-13 of macrophages themselves
and this leads to auto- and paracrine induction of arginase I
expression in macrophages (68). It has long been known that
murine DCs share the fundamental arginase/iNOS polarization
with macrophages (113). A novel aspect here is that DCs produce
RA, which then induces arginase I and the arginine transporter
CAT-2B in the DCs themselves (34). This RA-mediated autocrine–
paracrine induction of arginase I in DCs is induced by binding of
RA to an RA-responsive element in the 5′ non-coding region of
the arginase I gene and is enhanced by known exogenous arginase
inducers like IL-4 or GM-CSF (34).
M1/M2 POLARIZATION IN VIVO
In human tuberculosis, the distribution of M1 (iNOS) and M2
(arginase) macrophages is spatially organized within granulo-
mas: M1 macrophages can preferentially be found in the inner
region closer to viable mycobacteria, whereas a higher frequency
of M2 macrophages is detectable on the outer “healing” mar-
gins. This clearly forms an organized microenvironment in which
antibacterial (M1) responses are physically separated by M2-
based anti-inflammation and fibrosis from uninvolved tissue (96).
In a murine tuberculosis model, overexpression of IL-13 pre-
cipitates expansion of the M2 arginase-expressing macrophage
response to the pathogens recapitulating human pathology of
post-primary tuberculosis, while the endogenous inhibition of
arginase I expression via NOHA restrains arginase expression
and pathology (114). This is in line with an earlier study show-
ing a disease-exacerbating role of macrophage arginase (67). In
contrast to the latter two reports, a recently published study
analyzed the role of macrophage arginase in a hypoxic model
of Mycobacterium tuberculosis granuloma formation, in which
iNOS-based synthesis of RNS is impaired and which likely reflects
in vivo reality. Here, it was shown that arginase I expression in
granuloma-associated macrophages restricts immune pathology
since macrophage-specific deletion of arginase I led to larger gran-
ulomas and bacterial burden load (115). These discrepant study
results clearly demonstrate the fundamental importance of the
microenvironment and the multitude of potential factors that act
on macrophages in vivo and which can simply not be mimicked
in vitro.
SUMMARY AND OUTLOOK
The concept of macrophage M1/M2 dichotomy, based on differ-
ential usage of arginine via NOS or arginase was born 25 years
ago based on analyses of healing wounds (5, 104). Since then,
we have witnessed a bewildering explosion of knowledge regard-
ing macrophage surface markers, activation requirements, signal
transduction elements and gene regulation. Within this universe of
complexity the simple discriminator arginase versus NOS expres-
sion has not only remained valid to explain how a mammalian
organism deals with wounding (which is important enough in
itself) but also has demonstrated enormous power to better explain
and understand such diverse problems as cancer control ver-
sus cancer-induced immunosuppression, autoimmune pathology
versus preservation of tolerance to self, infection control versus
chronicity or death due to infection as well as tissue healing ver-
sus exaggerated fibrosis. Despite this scientific progress during
the last quarter-century, we have by far not reached the sum-
mit of the Everest, but rather a solid base camp I, in which to
plan and prepare the next steps. The arginase/iNOS dichotomy
of macrophage amino acid metabolism has counterparts in the
other major components of cellular metabolism: (a) genes of fatty
acid oxidation are preferentially expressed in M2 macrophages and
inhibition of fatty acid oxidation leads to an abrogation of M2
activation (116); (b) M1 macrophages preferentially use glycolysis
and glutamine anaplerosis while M2 macrophages preferentially
use oxidative metabolism (117). The emerging interconnections
between macrophage metabolism and M1/M2 polarization (118)
have recently been reviewed (119, 120) and we anticipate excit-
ing progress in this field in the upcoming years. Another crucial
aspect of the M1/M2 dichotomy that eagerly awaits more progress
and clarification is the current discrepancy between murine and
human macrophage biology in terms of iNOS/arginase expression
and regulation (17, 42, 121). We definitely need more carefully
executed in vivo and ex vivo analyses of human macrophage acti-
vation phenotypes in diverse disease settings. This will then also
lay the foundation for targeted therapeutic intervention to har-
ness the enormous power of the arginine metabolic phenotypes
of M1/M2 macrophage polarization.
ACKNOWLEDGMENTS
Supported by the Deutsche Forschungsgemeinschaft (MU 1547/4-
1 to Markus Munder and Cl100/6-1 to Ellen I. Closs).
REFERENCES
1. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage sub-
sets. Nat Rev Immunol (2011) 11:723–37. doi:10.1038/nri3073
www.frontiersin.org October 2014 | Volume 5 | Article 532 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rath et al. Macrophage arginine metabolism
2. Gordon S, Martinez FO. Alternative activation of macrophages: mecha-
nism and functions. Immunity (2010) 32:593–604. doi:10.1016/j.immuni.
2010.05.007
3. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas.
J Clin Invest (2012) 122:787–95. doi:10.1172/JCI59643
4. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al.
Macrophage activation and polarization: nomenclature and experimental
guidelines. Immunity (2014) 41:14–20. doi:10.1016/j.immuni.2014.06.008
5. Mills CD. M1 and M2 macrophages: oracles of health and disease. Crit Rev
Immunol (2012) 32(6):463–88. doi:10.1615/CritRevImmunol.v32.i6.10
6. Boger RH, Bode-Boger SM. The clinical pharmacology of L-arginine. Annu Rev
Pharmacol Toxicol (2001) 41:79–99. doi:10.1146/annurev.pharmtox.41.1.79
7. Morris SM Jr. Arginine: beyond protein. Am J Clin Nutr (2006) 83:508S–12S.
8. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem
J (1998) 336:1–17.
9. Windmueller HG, Spaeth AE. Source and fate of circulating citrulline. Am
J Physiol (1981) 241:E473–80.
10. Hibbs JB Jr, Taintor RR, Vavrin Z. Macrophage cytotoxicity: role for L-arginine
deiminase and imino nitrogen oxidation to nitrite. Science (1987) 235:473–6.
doi:10.1126/science.2432665
11. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the
biological activity of endothelium-derived relaxing factor. Nature (1987)
327:524–6. doi:10.1038/327524a0
12. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived
relaxing factor produced and released from artery and vein is nitric oxide. Proc
Natl Acad Sci U S A (1987) 84:9265–9. doi:10.1073/pnas.84.24.9265
13. Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic acti-
vated macrophage effector molecule. Biochem Biophys Res Commun (1988)
157:87–94. doi:10.1016/S0006-291X(88)80015-9
14. Marletta MA, Yoon PS, Iyengar R, Leaf CD, Wishnok JS. Macrophage oxidation
of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry
(1988) 27:8706–11. doi:10.1021/bi00424a003
15. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric
oxide from L-arginine. Nature (1988) 333:664–6. doi:10.1038/333664a0
16. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to ther-
apy. Immunity (2014) 41:49–61. doi:10.1016/j.immuni.2014.06.010
17. Munder M. Arginase: an emerging key player in the mammalian immune sys-
tem. Br J Pharmacol (2009) 158:638–51. doi:10.1111/j.1476-5381.2009.00291.x
18. Raber P, Ochoa AC, Rodriguez PC. Metabolism of L-arginine by myeloid-
derived suppressor cells in cancer: mechanisms of T cell suppression and ther-
apeutic perspectives. Immunol Invest (2012) 41:614–34. doi:10.3109/08820139.
2012.680634
19. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of
the immune system. Nat Rev Immunol (2009) 9:162–74. doi:10.1038/nri2506
20. Kropf P, Baud D, Marshall SE, Munder M, Mosley A, Fuentes JM, et al. Arginase
activity mediates reversible T cell hyporesponsiveness in human pregnancy. Eur
J Immunol (2007) 37:935–45. doi:10.1002/eji.200636542
21. Muller I, Munder M, Kropf P, Hansch GM. Polymorphonuclear neutrophils
and T lymphocytes: strange bedfellows or brothers in arms? Trends Immunol
(2009) 30:522–30. doi:10.1016/j.it.2009.07.007
22. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu
Rev Immunol (1997) 15:323–50. doi:10.1146/annurev.immunol.15.1.323 Epub
1997/01/01. ,
23. Stuehr DJ. Mammalian nitric oxide synthases. Biochim Biophys Acta (1999)
1411:217–30. doi:10.1016/S0005-2728(99)00016-X
24. Nussler AK, Billiar TR, Liu ZZ, Morris SM Jr. Coinduction of nitric oxide
synthase and argininosuccinate synthetase in a murine macrophage cell line.
Implications for regulation of nitric oxide production. J Biol Chem (1994)
269:1257–61.
25. Baydoun AR, Bogle RG, Pearson JD, Mann GE. Discrimination between cit-
rulline and arginine transport in activated murine macrophages: inefficient
synthesis of NO from recycling of citrulline to arginine. Br J Pharmacol (1994)
112:487–92. doi:10.1111/j.1476-5381.1994.tb13099.x
26. Mori M. Regulation of nitric oxide synthesis and apoptosis by arginase and
arginine recycling. J Nutr (2007) 137:1616S–20S.
27. Qualls JE, Subramanian C, Rafi W, Smith AM, Balouzian L, DeFreitas AA, et al.
Sustained generation of nitric oxide and control of mycobacterial infection
requires argininosuccinate synthase 1. Cell Host Microbe (2012) 12:313–23.
doi:10.1016/j.chom.2012.07.012
28. Yeramian A, Martin L, Serrat N, Arpa L, Soler C, Bertran J, et al. Arginine trans-
port via cationic amino acid transporter 2 plays a critical regulatory role in clas-
sical or alternative activation of macrophages. J Immunol (2006) 176:5918–24.
doi:10.4049/jimmunol.176.10.5918
29. Rothenberg ME, Doepker MP, Lewkowich IP, Chiaramonte MG, Stringer KF,
Finkelman FD, et al. Cationic amino acid transporter 2 regulates inflamma-
tory homeostasis in the lung. Proc Natl Acad Sci U S A (2006) 103:14895–900.
doi:10.1073/pnas.0605478103
30. Closs EI, Simon A, Vekony N, Rotmann A. Plasma membrane transporters for
arginine. J Nutr (2004) 134:2752S–9S.
31. Closs EI, Boissel JP, Habermeier A, Rotmann A. Structure and function of
cationic amino acid transporters (CATs). J Membr Biol (2006) 213:67–77.
doi:10.1007/s00232-006-0875-7
32. Fotiadis D,KanaiY,Palacin M. The SLC3 and SLC7 families of amino acid trans-
porters. Mol Aspects Med (2013) 34:139–58. doi:10.1016/j.mam.2012.10.007
33. Hatzoglou M, Fernandez J, Yaman I, Closs E. Regulation of cationic amino acid
transport: the story of the CAT-1 transporter. Annu Rev Nutr (2004) 24:377–99.
doi:10.1146/annurev.nutr.23.011702.073120
34. Chang J, Thangamani S, Kim MH, Ulrich B, Moris SM Jr, Kim CH. Retinoic
acid promotes the development of Arg1-expressing dendritic cells for the regu-
lation of T-cell differentiation. Eur J Immunol (2013) 43:967–78. doi:10.1002/
eji.201242772
35. Kawahara K, Gotoh T, Oyadomari S, Kajizono M, Kuniyasu A, Ohsawa
K, et al. Co-induction of argininosuccinate synthetase, cationic amino acid
transporter-2, and nitric oxide synthase in activated murine microglial cells.
Brain Res Mol Brain Res (2001) 90:165–73. doi:10.1016/S0169-328X(01)
00100-0
36. Niese KA, Chiaramonte MG, Ellies LG, Rothenberg ME, Zimmermann N. The
cationic amino acid transporter 2 is induced in inflammatory lung models and
regulates lung fibrosis. Respir Res (2010) 11:87. doi:10.1186/1465-9921-11-87
37. Nicholson B, Manner CK, Kleeman J, MacLeod CL. Sustained nitric oxide pro-
duction in macrophages requires the arginine transporter CAT2. J Biol Chem
(2001) 276:15881–5. doi:10.1074/jbc.M010030200
38. Sans-Fons MG, Yeramian A, Pereira-Lopes S, Santamaria-Babi LF, Modolell M,
Lloberas J, et al. Arginine transport is impaired in C57Bl/6 mouse macrophages
as a result of a deletion in the promoter of Slc7a2 (CAT2), and suscepti-
bility to Leishmania infection is reduced. J Infect Dis (2013) 207:1684–93.
doi:10.1093/infdis/jit084
39. Rotoli BM, Bussolati O, Sala R, Barilli A, Talarico E, Gazzola GC, et al.
INFgamma stimulates arginine transport through system y+L in human mono-
cytes. FEBS Lett (2004) 571:177–81. doi:10.1016/j.febslet.2004.06.086
40. Rotoli BM, Dall’asta V, Barilli A, D’Ippolito R, Tipa A, Olivieri D, et al.
Alveolar macrophages from normal subjects lack the NOS-related system
y+ for arginine transport. Am J Respir Cell Mol Biol (2007) 37:105–12.
doi:10.1165/rcmb.2006-0262OC
41. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, Fuentes JM,
et al. Arginase I is constitutively expressed in human granulocytes and par-
ticipates in fungicidal activity. Blood (2005) 105:2549–56. doi:10.1182/blood-
2004-07-2521
42. Raes G, Van den Bergh R, De Baetselier P, Ghassabeh GH, Scotton C, Locati M,
et al. Arginase-1 and Ym1 are markers for murine, but not human, alternatively
activated myeloid cells. J Immunol (2005) 174:6561. doi:10.4049/jimmunol.
174.11.6561
43. Closs EI, Scheld JS, Sharafi M, Forstermann U. Substrate supply for nitric-
oxide synthase in macrophages and endothelial cells: role of cationic amino
acid transporters. Mol Pharmacol (2000) 57:68–74.
44. Taylor PM. Amino acid transporters: eminences grises of nutrient signalling
mechanisms? Biochem Soc Trans (2009) 37:237–41. doi:10.1042/BST0370237
45. Kaneko S, Okuda-Ashitaka E, Ando A, Nishimura K, Igarashi K, Maeda M,
et al. Polyamines upregulate the mRNA expression of cationic amino acid
transporter-1 in human retinal pigment epithelial cells. Am J Physiol Cell Physiol
(2007) 293:C729–37. doi:10.1152/ajpcell.00018.2007
46. Rotondo R, Barisione G, Mastracci L, Grossi F, Orengo AM, Costa R, et al.
IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears
in nonsmall cell lung cancer. Int J Cancer (2009) 125:887–93. doi:10.1002/
ijc.24448
47. Munder M, Schneider H, Luckner C, Giese T, Langhans CD, Fuentes JM, et al.
Suppression of T-cell functions by human granulocyte arginase. Blood (2006)
108:1627–34. doi:10.1182/blood-2006-11-010389
Frontiers in Immunology | Inflammation October 2014 | Volume 5 | Article 532 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rath et al. Macrophage arginine metabolism
48. Furchgott RF. The role of endothelium in the responses of vascular smooth
muscle to drugs. Annu Rev Pharmacol Toxicol (1984) 24:175–97. doi:10.1146/
annurev.pa.24.040184.001135
49. Stuehr DJ, Marletta MA. Mammalian nitrate biosynthesis: mouse macrophages
produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide.
Proc Natl Acad Sci U S A (1985) 82:7738–42. doi:10.1073/pnas.82.22.7738
50. Stuehr DJ, Marletta MA. Induction of nitrite/nitrate synthesis in murine
macrophages by BCG infection, lymphokines, or interferon-gamma. J Immunol
(1987) 139:518–25.
51. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned
and expressed nitric oxide synthase structurally resembles cytochrome P-450
reductase. Nature (1991) 351:714–8. doi:10.1038/351714a0
52. Lyons CR, Orloff GJ, Cunningham JM. Molecular cloning and functional
expression of an inducible nitric oxide synthase from a murine macrophage
cell line. J Biol Chem (1992) 267:6370–4.
53. Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, et al.
Cloning and characterization of inducible nitric oxide synthase from mouse
macrophages. Science (1992) 256:225–8. doi:10.1126/science.1373522
54. Michel T, Lamas S. Molecular cloning of constitutive endothelial nitric oxide
synthase: evidence for a family of related genes. J Cardiovasc Pharmacol (1992)
20:S45–9. doi:10.1097/00005344-199204002-00014
55. Geller DA, Lowenstein CJ, Shapiro RA, Nussler AK, Di Silvio M, Wang
SC, et al. Molecular cloning and expression of inducible nitric oxide syn-
thase from human hepatocytes. Proc Natl Acad Sci U S A (1993) 90:3491–5.
doi:10.1073/pnas.90.2.522
56. Asano K, Chee CB, Gaston B, Lilly CM, Gerard C, Drazen JM, et al. Constitutive
and inducible nitric oxide synthase gene expression, regulation, and activity in
human lung epithelial cells. Proc Natl Acad Sci U S A (1994) 91:10089–93.
doi:10.1073/pnas.91.21.10089
57. Perner A, Andresen L, Normark M, Rask-Madsen J. Constitutive expression of
inducible nitric oxide synthase in the normal human colonic epithelium. Scand
J Gastroenterol (2002) 37:944–8. doi:10.1080/003655202760230919
58. Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. Reciprocal regulation
of the nitric oxide synthase/arginase balance in mouse bone marrow-derived
macrophages by TH1 and TH2 cytokines. Eur J Immunol (1995) 25:1101–4.
doi:10.1002/eji.1830250436
59. El-Gayar S, Thuring-Nahler H, Pfeilschifter J, Rollinghoff M, Bogdan C.
Translational control of inducible nitric oxide synthase by IL-13 and argi-
nine availability in inflammatory macrophages. J Immunol (2003) 171:4561–8.
doi:10.4049/jimmunol.171.9.4561
60. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide.
Annu Rev Pharmacol Toxicol (1990) 30:535–60. doi:10.1146/annurev.pa.30.
040190.002535
61. Jenkinson CP, Grody WW, Cederbaum SD. Comparative properties of
arginases. Comp Biochem Physiol B Biochem Mol Biol (1996) 114:107–32.
doi:10.1016/0305-0491(95)02138-8
62. Corraliza IM, Soler G, Eichmann K, Modolell M. Arginase induction by
suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine
bone-marrow-derived macrophages. Biochem Biophys Res Commun (1995)
206:667–73. doi:10.1006/bbrc.1995.1094
63. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine
macrophages reflected by the nitric oxide synthase/arginase balance: competi-
tive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol
(1998) 160:5347–54.
64. Pauleau AL, Rutschman R, Lang R, Pernis A, Watowich SS, Murray PJ.
Enhancer-mediated control of macrophage-specific arginase I expression.
J Immunol (2004) 172:7565–73. doi:10.4049/jimmunol.172.12.7565
65. Erdely A, Kepka-Lenhart D, Clark M, Zeidler-Erdely P, Poljakovic M, Calhoun
WJ, et al. Inhibition of phosphodiesterase 4 amplifies cytokine-dependent
induction of arginase in macrophages. Am J Physiol Lung Cell Mol Physiol
(2006) 290:L534–9. doi:10.1152/ajplung.00326.2005
66. Sheldon KE, Shandilya H, Kepka-Lenhart D, Poljakovic M, Ghosh A, Morris
SM Jr. Shaping the murine macrophage phenotype: IL-4 and cyclic AMP syn-
ergistically activate the arginase I promoter. J Immunol (2013) 191:2290–8.
doi:10.4049/jimmunol.1202102
67. El Kasmi KC, Qualls JE, Pesce JT, Smith AM, Thompson RW, Henao-Tamayo
M, et al. Toll-like receptor-induced arginase 1 in macrophages thwarts effective
immunity against intracellular pathogens. Nat Immunol (2008) 9:1399–406.
doi:10.1038/ni.1671
68. Shirey KA, Pletneva LM, Puche AC, Keegan AD, Prince GA, Blanco JC, et al.
Control of RSV-induced lung injury by alternatively activated macrophages
is IL-4R alpha-, TLR4-, and IFN-beta-dependent. Mucosal Immunol (2010)
3:291–300. doi:10.1038/mi.2010.6
69. Tabor CW, Tabor H. Polyamines. Annu Rev Biochem (1984) 53:749–90.
doi:10.1146/annurev.bi.53.070184.003533
70. Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life (2009)
61:880–94. doi:10.1002/iub.230
71. Zhang M, Caragine T, Wang H, Cohen PS, Botchkina G, Soda K, et al. Spermine
inhibits proinflammatory cytokine synthesis in human mononuclear cells: a
counterregulatory mechanism that restrains the immune response. J Exp Med
(1997) 185:1759–68. doi:10.1084/jem.185.10.1759
72. Mossner J, Hammermann R, Racke K. Concomitant down-regulation of L-
arginine transport and nitric oxide (NO) synthesis in rat alveolar macrophages
by the polyamine spermine. Pulm Pharmacol Ther (2001) 14:297–305. doi:10.
1006/pupt.2001.0297
73. Szabo C, Southan GJ, Thiemermann C, Vane JR. The mechanism of the
inhibitory effect of polyamines on the induction of nitric oxide synthase: role of
aldehyde metabolites. Br J Pharmacol (1994) 113:757–66. doi:10.1111/j.1476-
5381.1994.tb17058.x
74. Kitowska K, Zakrzewicz D, Konigshoff M, Chrobak I, Grimminger F, Seeger
W, et al. Functional role and species-specific contribution of arginases in
pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2008) 294:L34–45.
doi:10.1152/ajplung.00007.2007
75. Zimmermann N, King NE, Laporte J, Yang M, Mishra A, Pope SM, et al.
Dissection of experimental asthma with DNA microarray analysis iden-
tifies arginase in asthma pathogenesis. J Clin Invest (2003) 111:1863–74.
doi:10.1172/JCI17912
76. Maarsingh H, Dekkers BG, Zuidhof AB, Bos IS, Menzen MH, Klein
T, et al. Increased arginase activity contributes to airway remodelling in
chronic allergic asthma. Eur Respir J (2011) 38:318–28. doi:10.1183/09031936.
00057710
77. Albina JE, Mills CD, Barbul A, Thirkill CE, Henry WL Jr, Mastrofrancesco B,
et al. Arginine metabolism in wounds. Am J Physiol (1988) 254:E459–67.
78. Albina JE, Mills CD, Henry WL Jr, Caldwell MD. Temporal expression of differ-
ent pathways of 1-arginine metabolism in healing wounds. J Immunol (1990)
144:3877–80.
79. Mills CD, Shearer J, Evans R, Caldwell MD. Macrophage arginine metabolism
and the inhibition or stimulation of cancer. J Immunol (1992) 149:2709–14.
80. Herbert DR, Orekov T, Roloson A, Ilies M, Perkins C, O’Brien W, et al.
Arginase I suppresses IL-12/IL-23p40-driven intestinal inflammation during
acute schistosomiasis. J Immunol (2010) 184:6438–46. doi:10.4049/jimmunol.
0902009
81. Narita Y, Kitamura H, Wakita D, Sumida K, Masuko K, Terada S, et al. The key
role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+)
T cell dysfunction in tumor-bearing mice. J Immunol (2013) 190:812–20.
doi:10.4049/jimmunol.1103797
82. Lewis ND, Asim M, Barry DP, de Sablet T, Singh K, Piazuelo MB, et al. Immune
evasion by Helicobacter pylori is mediated by induction of macrophage arginase
II. J Immunol (2011) 186:3632–41. doi:10.4049/jimmunol.1003431
83. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC,
Smith AM, et al. Arginase-1-expressing macrophages suppress Th2 cytokine-
driven inflammation and fibrosis. PLoS Pathog (2009) 5:e1000371. doi:10.
1371/journal.ppat.1000371
84. Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever
AW, et al. Differential regulation of nitric oxide synthase-2 and arginase-1
by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by
the pattern of L-arginine metabolism. J Immunol (2001) 167(11):6533–44.
doi:10.4049/jimmunol.167.11.6533
85. Kropf P, Fuentes JM, Fahnrich E, Arpa L, Herath S, Weber V, et al. Arginase and
polyamine synthesis are key factors in the regulation of experimental leishma-
niasis in vivo. FASEB J (2005) 19:1000–2. doi:10.1096/fj.04-3416fje
86. Abebe T, Takele Y, Weldegebreal T, Cloke T, Closs E, Corset C, et al. Arginase
activity – a marker of disease status in patients with visceral leishmaniasis
in ethiopia. PLoS Negl Trop Dis (2013) 7:e2134. doi:10.1371/journal.pntd.
0002134
87. Takele Y, Abebe T, Weldegebreal T, Hailu A, Hailu W, Hurissa Z, et al. Arginase
activity in the blood of patients with visceral leishmaniasis and HIV infection.
PLoS Negl Trop Dis (2013) 7:e1977. doi:10.1371/journal.pntd.0001977
www.frontiersin.org October 2014 | Volume 5 | Article 532 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rath et al. Macrophage arginine metabolism
88. Cloke TE, Garvey L, Choi BS, Abebe T, Hailu A, Hancock M, et al. Increased
level of arginase activity correlates with disease severity in HIV-seropositive
patients. J Infect Dis (2010) 202:374–85. doi:10.1086/653736
89. Rodriguez PC, Hernandez CP, Morrow K, Sierra R, Zabaleta J, Wyczechowska
DD, et al. L-arginine deprivation regulates cyclin D3 mRNA stability in human
T cells by controlling HuR expression. J Immunol (2010) 185:5198–204.
doi:10.4049/jimmunol.1001224
90. Munder M, Choi BS, Rogers M, Kropf P. L-arginine deprivation impairs Leish-
mania major-specific T-cell responses. Eur J Immunol (2009) 39:2161–72.
doi:10.1002/eji.200839041
91. Feldmeyer N,Wabnitz G, Leicht S, Luckner-Minden C, Schiller M, Franz T, et al.
Arginine deficiency leads to impaired cofilin dephosphorylation in activated
human T lymphocytes. Int Immunol (2012) 24:303–13. doi:10.1093/intimm/
dxs004
92. Modolell M, Choi BS, Ryan RO, Hancock M, Titus RG,Abebe T, et al. Local sup-
pression of T cell responses by arginase-induced L-arginine depletion in non-
healing leishmaniasis. PLoS Negl Trop Dis (2009) 3:e480. doi:10.1371/journal.
pntd.0000480
93. Mieulet V, Yan L, Choisy C, Sully K, Procter J, Kouroumalis A, et al. TPL-2-
mediated activation of MAPK downstream of TLR4 signaling is coupled to
arginine availability. Sci Signal (2010) 3:ra61. doi:10.1126/scisignal.2000934
94. Munder M, Engelhardt M, Knies D, Medenhoff S, Wabnitz G, Luckner-Minden
C, et al. Cytotoxicity of tumor antigen specific human T cells is unimpaired
by arginine depletion. PLoS One (2013) 8:e63521. doi:10.1371/journal.pone.
0063521
95. Kapp K, Prufer S, Michel CS, Habermeier A, Luckner-Minden C, Giese T, et al.
Granulocyte functions are independent of arginine availability. J Leukoc Biol
(2014). doi:10.1189/jlb.3AB0214-082R
96. Mattila JT, Ojo OO, Kepka-Lenhart D, Marino S, Kim JH, Eum SY, et al.
Microenvironments in Tuberculous granulomas are delineated by distinct
populations of macrophage subsets and expression of nitric oxide synthase
and arginase isoforms. J Immunol (2013) 191:773–84. doi:10.4049/jimmunol.
1300113
97. Hecker M, Nematollahi H, Hey C, Busse R, Racke K. Inhibition of arginase
by NG-hydroxy-L-arginine in alveolar macrophages: implications for the uti-
lization of L-arginine for nitric oxide synthesis. FEBS Lett (1995) 359:251–4.
doi:10.1016/0014-5793(95)00039-C
98. Bauer PM, Fukuto JM, Buga GM, Pegg AE, Ignarro LJ. Nitric oxide inhibits
ornithine decarboxylase by S-nitrosylation. Biochem Biophys Res Commun
(1999) 262:355–8. doi:10.1006/bbrc.1999.1210
99. Hey C, Boucher JL, Vadon-Le Goff S, Ketterer G, Wessler I, Racke K. Inhibi-
tion of arginase in rat and rabbit alveolar macrophages by N omega-hydroxy-
D,L-indospicine, effects on L-arginine utilization by nitric oxide synthase. Br
J Pharmacol (1997) 121:395–400. doi:10.1038/sj.bjp.0701143
100. Lee J, Ryu H, Ferrante RJ, Morris SM Jr, Ratan RR. Translational control of
inducible nitric oxide synthase expression by arginine can explain the argi-
nine paradox. Proc Natl Acad Sci U S A (2003) 100:4843–8. doi:10.1073/pnas.
0735876100
101. Southan GJ, Szabo C, Thiemermann C. Inhibition of the induction of nitric
oxide synthase by spermine is modulated by aldehyde dehydrogenase. Biochem
Biophys Res Commun (1994) 203:1638–44. doi:10.1006/bbrc.1994.2374
102. Baydoun AR, Morgan DM. Inhibition of ornithine decarboxylase potentiates
nitric oxide production in LPS-activated J774 cells. Br J Pharmacol (1998)
125:1511–6. doi:10.1038/sj.bjp.0702231
103. Bussiere FI, Chaturvedi R, Cheng Y, Gobert AP, Asim M, Blumberg DR, et al.
Spermine causes loss of innate immune response to Helicobacter pylori by
inhibition of inducible nitric-oxide synthase translation. J Biol Chem (2005)
280:2409–12. doi:10.1074/jbc.C400498200
104. Mills CD, Ley K. M1 and M2 macrophages: the chicken and the egg of immu-
nity. J Innate Immun (2014) 6:716–26. doi:10.1159/000364945
105. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Func-
tional polarization of tumour-associated macrophages by tumour-derived lac-
tic acid. Nature (2014) 513:559–63. doi:10.1038/nature13490
106. Barilli A, Rotoli BM, Visigalli R, Dall’Asta V. Gliadin activates arginase path-
way in RAW264.7 cells and in human monocytes. Biochim Biophys Acta (2014)
1842:1364–71. doi:10.1016/j.bbadis.2014.04.021
107. Osorio EY, Travi BL, da Cruz AM, Saldarriaga OA, Medina AA, Melby PC.
Growth factor and Th2 cytokine signaling pathways converge at STAT6 to pro-
mote arginase expression in progressive experimental visceral leishmaniasis.
PLoS Pathog (2014) 10:e1004165. doi:10.1371/journal.ppat.1004165
108. Tao B, Jin W, Xu J, Liang Z, Yao J, Zhang Y, et al. Myeloid-specific disruption
of tyrosine phosphatase shp2 promotes alternative activation of macrophages
and predisposes mice to pulmonary fibrosis. J Immunol (2014) 193:2801–11.
doi:10.4049/jimmunol.1303463
109. Sahin E, Haubenwallner S, Kuttke M, Kollmann I, Halfmann A, Dohnal AB,
et al. Macrophage PTEN regulates expression and secretion of arginase I modu-
lating innate and adaptive immune responses. J Immunol (2014) 193:1717–27.
doi:10.4049/jimmunol.1302167
110. Rauh MJ, Ho V, Pereira C, Sham A, Sly LM, Lam V, et al. SHIP represses the gen-
eration of alternatively activated macrophages. Immunity (2005) 23:361–74.
doi:10.1016/j.immuni.2005.09.003
111. Serrat N, Pereira-Lopes S, Comalada M, Lloberas J, Celada A. Deacetylation
of C/EBPbeta is required for IL-4-induced arginase-1 expression in murine
macrophages. Eur J Immunol (2012) 42:3028–37. doi:10.1002/eji.201242413
112. Qualls JE, Neale G, Smith AM, Koo MS, DeFreitas AA, Zhang H, et al. Arginine
usage in mycobacteria-infected macrophages depends on autocrine-paracrine
cytokine signaling. Sci Signal (2010) 3:ra62. doi:10.1126/scisignal.2000955
113. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M. Th1/Th2-
regulated expression of arginase isoforms in murine macrophages and den-
dritic cells. J Immunol (1999) 163:3771–7.
114. Heitmann L, Abad Dar M, Schreiber T, Erdmann H, Behrends J, McKenzie AN,
et al. The IL-13/IL-4Ralpha axis is involved in tuberculosis-associated pathol-
ogy. J Pathol (2014) 234:338–50. doi:10.1002/path.4399
115. Duque-Correa MA, Kuhl AA, Rodriguez PC, Zedler U, Schommer-Leitner S,
Rao M, et al. Macrophage arginase-1 controls bacterial growth and pathol-
ogy in hypoxic tuberculosis granulomas. Proc Natl Acad Sci U S A (2014)
111:E4024–32. doi:10.1073/pnas.1408839111
116. Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, Morel CR, et al. Oxida-
tive metabolism and PGC-1beta attenuate macrophage-mediated inflamma-
tion. Cell Metab (2006) 4:13–24. doi:10.1016/j.cmet.2006.08.006
117. Ganeshan K, Chawla A. Metabolic regulation of immune responses. Annu Rev
Immunol (2014) 32:609–34. doi:10.1146/annurev-immunol-032713-120236
118. Lamour SD, Choi BS, Keun HC, Muller I, Saric J. Metabolic characterization
of Leishmania major infection in activated and nonactivated macrophages.
J Proteome Res (2012) 11:4211–22. doi:10.1021/pr3003358
119. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell
Metab (2012) 15:432–7. doi:10.1016/j.cmet.2011.11.013
120. Ghesquiere B, Wong BW, Kuchnio A, Carmeliet P. Metabolism of stro-
mal and immune cells in health and disease. Nature (2014) 511:167–76.
doi:10.1038/nature13312
121. Murray PJ, Wynn TA. Obstacles and opportunities for understanding
macrophage polarization. J Leukoc Biol (2011) 89:557–63. doi:10.1189/jlb.
0710409
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 24 September 2014; paper pending published: 07 October 2014; accepted: 09
October 2014; published online: 27 October 2014.
Citation: Rath M, Müller I, Kropf P, Closs EI and Munder M (2014) Metabolism via
arginase or nitric oxide synthase: two competing arginine pathways in macrophages.
Front. Immunol. 5:532. doi: 10.3389/fimmu.2014.00532
This article was submitted to Inflammation, a section of the journal Frontiers in
Immunology.
Copyright © 2014 Rath, Müller , Kropf, Closs and Munder. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | Inflammation October 2014 | Volume 5 | Article 532 | 10
